Corvus Pharmaceuticals (CRVS) Short Interest Ratio & Short Volume $5.61 +0.13 (+2.37%) (As of 09/19/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Corvus Pharmaceuticals Short Interest DataCorvus Pharmaceuticals (CRVS) has a short interest of 1.43 million shares. This marks a 4.38% increase in short interest from the previous month. The short interest ratio (days to cover) is 4.9, indicating that it would take 4.9 days of the average trading volume of 267,717 shares to cover all short positions.Current Short Interest1,430,000 sharesPrevious Short Interest1,370,000 sharesChange Vs. Previous Month+4.38%Dollar Volume Sold Short$6.41 millionShort Interest Ratio4.9 Days to CoverLast Record DateAugust 31, 2024Outstanding Shares62,551,000 sharesPercentage of Shares Shorted2.29%Today's Trading Volume275,961 sharesAverage Trading Volume267,717 sharesToday's Volume Vs. Average103% Short Selling Corvus Pharmaceuticals? Sign up to receive the latest short interest report for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCRVS Short Interest Over TimeCRVS Days to Cover Over TimeCRVS Percentage of Float Shorted Over Time Ad Weiss RatingsWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” Corvus Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/31/20241,430,000 shares $6.41 million +4.4%N/A4.9 $4.48 8/15/20241,370,000 shares $5.21 million +19.1%N/A5.3 $3.80 7/31/20241,150,000 shares $2.96 million -8.0%N/A4.7 $2.57 7/15/20241,250,000 shares $2.50 million -12.6%N/A5.8 $2.00 6/30/20241,430,000 shares $2.60 million -4.7%N/A6.6 $1.82 6/15/20241,500,000 shares $3.06 million -1.3%N/A6.5 $2.04 Get the Latest News and Ratings for CRVS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/31/20241,520,000 shares $3.28 million +17.8%N/A6.5 $2.16 5/15/20241,290,000 shares $2.86 million -5.2%N/A5.2 $2.22 4/30/20241,360,000 shares $2.11 million -0.7%3.7%5.4 $1.55 4/15/20241,370,000 shares $2.01 million -2.1%3.7%7 $1.47 3/31/20241,400,000 shares $2.49 million -6.0%3.8%6.6 $1.78 3/15/20241,490,000 shares $2.83 million +17.3%4.0%6.8 $1.90 2/29/20241,270,000 shares $2.84 million No Change3.4%5.7 $2.24 2/15/20241,270,000 shares $2.98 million -8.0%3.4%6.2 $2.35 1/31/20241,380,000 shares $2.76 million -1.4%3.7%6.3 $2.00 1/15/20241,400,000 shares $3.28 million +5.3%3.8%6 $2.34 12/31/20231,330,000 shares $2.34 million +2.3%3.6%6.1 $1.76 12/15/20231,300,000 shares $1.99 million -17.2%3.5%6.5 $1.53 11/30/20231,570,000 shares $2.40 million -12.3%4.3%7.9 $1.53 11/15/20231,790,000 shares $2.70 million +4.7%4.9%6.4 $1.51 10/31/20231,710,000 shares $1.93 million -3.4%4.6%6.4 $1.13 10/15/20231,770,000 shares $2.48 million No Change4.8%7.1 $1.40 9/30/20231,770,000 shares $2.58 million -2.8%4.8%6.1 $1.46 9/15/20231,820,000 shares $2.88 million +32.9%4.9%5 $1.58 8/31/20231,370,000 shares $2.90 million +21.2%3.8%2.3 $2.12 8/15/20231,130,000 shares $2.44 million -2.6%3.1%1.8 $2.16 7/31/20231,160,000 shares $2.61 million -17.7%3.4%1.1 $2.25 7/15/20231,410,000 shares $3.47 million +11.9%4.1%1.3 $2.46 6/30/20231,260,000 shares $2.89 million +61.4%3.7%1.1 $2.29 6/15/2023780,600 shares $1.94 million -19.8%2.3%0.7 $2.49 5/31/2023973,100 shares $2.96 million +113.6%2.8%1.1 $3.04 5/15/2023455,500 shares $1.18 million +209.2%1.3%0.6 $2.60 4/30/2023147,300 shares $159,084.00 -38.3%0.4%0.6 $1.08 4/15/2023238,700 shares $248,248.00 +50.8%0.7%1.1 $1.04 3/31/2023158,300 shares $144,053.00 -20.9%0.5%0.8 $0.91 3/15/2023200,200 shares $144,144.00 +16.9%0.6%2.1 $0.72 2/28/2023171,200 shares $124,976.00 +35.9%0.5%1.4 $0.73 2/15/2023126,000 shares $97,007.40 +13.7%0.4%1 $0.77 1/31/2023110,800 shares $90,856.00 -34.9%0.3%0.8 $0.82 1/15/2023170,100 shares $154,791.00 -3.7%0.5%1.2 $0.91Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” 12/30/2022176,700 shares $150,195.00 +17.3%0.5%1.2 $0.85 12/15/2022150,600 shares $126,353.40 -53.8%0.4%1 $0.84 11/30/2022325,900 shares $303,803.98 +58.1%0.9%2.2 $0.93 11/15/2022206,100 shares $187,963.20 -0.5%0.6%1.3 $0.91 10/31/2022207,100 shares $179,555.70 -12.4%0.6%1 $0.87 10/15/2022236,500 shares $215,215.00 +16.3%0.7%0.9 $0.91 9/30/2022203,300 shares $166,401.05 +1.6%0.6%0.7 $0.82 9/15/2022200,200 shares $191,191.00 +70.8%0.6%0.6 $0.96 8/31/2022117,200 shares $112,336.20 -64.5%0.3%0.4 $0.96 8/15/2022330,500 shares $371,812.50 -75.2%1.0%1.1 $1.13 7/31/20221,330,000 shares $1.17 million +70.1%3.9%4.7 $0.88 7/15/2022782,000 shares $774,962.00 -15.2%2.3%3.2 $0.99 6/30/2022922,500 shares $913,367.25 +306.2%2.7%3.6 $0.99 6/15/2022227,100 shares $224,806.29 +18.5%0.7%0.9 $0.99 5/31/2022191,600 shares $197,348.00 -22.9%0.6%0.8 $1.03 5/15/2022248,600 shares $258,544.00 +28.6%0.7%1 $1.04 4/30/2022193,300 shares $253,223.00 +5.2%0.6%0.8 $1.31 4/15/2022183,800 shares $266,510.00 -14.9%0.5%0.7 $1.45 3/31/2022215,900 shares $354,076.00 +5.2%0.6%0.7 $1.64 3/15/2022205,200 shares $299,592.00 +3.0%0.6%0.6 $1.46 2/28/2022199,200 shares $352,584.00 -41.3%0.6%0.5 $1.77 2/15/2022339,300 shares $692,172.00 +101.5%1.0%0.7 $2.04 1/31/2022168,400 shares $303,120.00 -43.8%0.5%0.3 $1.80 1/15/2022299,500 shares $673,875.00 +34.0%N/A0 $2.25 12/31/2021223,500 shares $538,635.00 -31.2%0.7%0.3 $2.41 12/15/2021324,700 shares $892,925.00 -43.0%1.0%0.2 $2.75 11/30/2021569,200 shares $1.94 million -45.8%1.9%0.1 $3.41 11/15/20211,050,000 shares $3.89 million -42.9%3.5%0.1 $3.70 10/29/20211,840,000 shares $8.34 million +3.4%6.2%0.2 $4.53 10/15/20211,780,000 shares $8.81 million -42.2%6.3%0.2 $4.95 9/30/20213,080,000 shares $14.91 million +318.7%10.9%0.4 $4.84 9/15/2021735,600 shares $1.68 million +45.0%2.5%0.1 $2.29 8/31/2021507,200 shares $1.15 million -48.0%1.8%2.1 $2.26 8/13/2021975,800 shares $1.93 million -22.6%3.5%4.4 $1.98 7/30/20211,260,000 shares $2.63 million +3.3%4.5%5.3 $2.09 7/15/20211,220,000 shares $2.84 million +0.8%3.7%4.1 $2.33 6/30/20211,210,000 shares $3.23 million +7.1%3.7%4.2 $2.67 6/15/20211,130,000 shares $3.10 million -8.9%3.4%3.5 $2.74 5/28/20211,240,000 shares $3.40 million +3.3%3.8%3.4 $2.74 5/14/20211,200,000 shares $2.95 million -9.1%N/A2.1 $2.46 4/30/20211,320,000 shares $3.72 million -1.5%N/A1.4 $2.82 4/15/20211,340,000 shares $3.79 million -7.6%N/A1.5 $2.83 3/31/20211,450,000 shares $4.26 million -8.2%N/A1.6 $2.94 3/15/20211,580,000 shares $5.10 million +24.4%N/A1.8 $3.23 2/26/20211,270,000 shares $4.55 million +2.4%N/A1.5 $3.58 2/12/20211,240,000 shares $4.89 million +0.8%N/A1.8 $3.94 1/29/20211,230,000 shares $4.54 million No Change5.7%5 $3.69 1/15/20211,230,000 shares $5.08 million +2.5%5.7%6.6 $4.13 12/31/20201,200,000 shares $4.52 million -3.2%5.6%6.8 $3.77 12/15/20201,240,000 shares $4.90 million -10.1%5.8%1.5 $3.95Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” 11/30/20201,380,000 shares $5.56 million -0.7%6.4%1.6 $4.03 11/15/20201,390,000 shares $5.74 million -9.2%6.5%1.6 $4.13 10/30/20201,530,000 shares $6.10 million +2.7%7.1%1.7 $3.99 10/15/20201,490,000 shares $5.96 million +8.8%6.9%1.6 $4.00 9/30/20201,370,000 shares $5.49 million -14.4%6.4%1.3 $4.01 9/15/20201,600,000 shares $6.75 million -1.2%7.5%0.8 $4.22 8/31/20201,620,000 shares $6.14 million +2.5%7.6%0.8 $3.79 8/14/20201,580,000 shares $6.35 million -2.5%7.4%0.8 $4.02 7/31/20201,620,000 shares $6.87 million +25.6%7.6%0.8 $4.24 7/15/20201,290,000 shares $4.91 million +204.1%6.0%0.6 $3.81 6/30/2020424,200 shares $1.15 million +0.3%2.1%0.2 $2.72 6/15/2020422,900 shares $1.31 million +29.0%2.1%3.2 $3.10 5/29/2020327,800 shares $1.20 million -72.5%1.7%2.2 $3.66 5/15/20201,190,000 shares $4.18 million -4.0%6.0%7.9 $3.51 4/30/20201,240,000 shares $3.14 million -1.6%5.4%8 $2.53 4/15/20201,260,000 shares $2.94 million No Change4.8%8.3 $2.33 3/31/20201,260,000 shares $3.38 million +1.0%5.9%7.4 $2.68 3/13/20201,248,100 shares $2.78 million -2.5%5.9%5.9 $2.23 2/28/20201,280,000 shares $2.60 million -3.8%6.0%6.1 $2.03 2/14/20201,330,000 shares $3.72 million +4.7%6.2%6.4 $2.80 1/31/20201,270,000 shares $4.71 million -5.9%6.0%6.3 $3.71 1/15/20201,350,000 shares $6.86 million -1.5%6.3%6.9 $5.08 12/31/20191,370,000 shares $7.96 million +1.5%6.4%7.6 $5.81 CRVS Short Interest - Frequently Asked Questions What is Corvus Pharmaceuticals' current short interest? Short interest is the volume of Corvus Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of August 31st, investors have sold 1,430,000 shares of CRVS short. Learn More on Corvus Pharmaceuticals' current short interest. What is a good short interest ratio for Corvus Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRVS shares currently have a short interest ratio of 5.0. Learn More on Corvus Pharmaceuticals's short interest ratio. Is Corvus Pharmaceuticals' short interest increasing or decreasing? Corvus Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,430,000 shares, an increase of 4.4% from the previous total of 1,370,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Corvus Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Corvus Pharmaceuticals: Enlivex Therapeutics Ltd. (0.45%), Orgenesis Inc. (0.86%), Aytu BioPharma, Inc. (5.62%), Ocular Therapeutix, Inc. (11.85%), Avadel Pharmaceuticals plc (12.39%), Xencor, Inc. (5.99%), Evotec SE (0.07%), ARS Pharmaceuticals, Inc. (22.54%), ANI Pharmaceuticals, Inc. (11.54%), Nurix Therapeutics, Inc. (18.84%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.11 billion), Canadian Natural Resources Limited ($4.04 billion), Suncor Energy Inc. ($3.19 billion), Aptiv PLC ($2.56 billion), Paychex, Inc. ($2.48 billion), Cencora, Inc. ($2.28 billion), Onsemi ($2.08 billion), Moderna, Inc. ($1.98 billion), Tractor Supply ($1.93 billion), and International Paper ($1.93 billion). View all of the most shorted stocks. What does it mean to sell short Corvus Pharmaceuticals stock? Short selling CRVS is an investing strategy that aims to generate trading profit from Corvus Pharmaceuticals as its price is falling. CRVS shares are trading up $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Corvus Pharmaceuticals? A short squeeze for Corvus Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CRVS, which in turn drives the price of the stock up even further. How often is Corvus Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRVS, twice per month. The most recent reporting period available is August, 31 2024. More Short Interest Resources from MarketBeat Related Companies: ENLV Short Interest Data ORGS Short Interest Data AYTU Short Interest Data OCUL Short Interest Data AVDL Short Interest Data XNCR Short Interest Data EVO Short Interest Data SPRY Short Interest Data ANIP Short Interest Data NRIX Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CRVS) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersAct by Friday, August 16th, to collect this 22% dividendLet's do a little math here... To double your money at a 3% rate of return, you would need around 23 years....Investors Alley | SponsoredWhy You Should NOT Trade This MarketYou'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this dif...InvestorPlace | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
